CMO Angel signs stem cell production deal

By Nick Taylor

- Last updated on GMT

Related tags Stem cell Biotechnology

Angel Biotechnology has inked a deal to manufacture the CTX stem cell line, which can now be frozen and thawed when needed, at its dedicated cell-based therapies plant that is equipped and licensed for the task.

Contract manufacturing organisations (CMO) offering stem cell production services in Europe require licenses from the Medicines and Healthcare Products Regulatory Agency (MHRA).

By gaining this at its Edinburgh, Scotland facility Angel has equipped itself to profit from rising demand for stem cell manufacturing. This is part of Angel’s efforts to develop the capacity to provide services “for such advanced biological therapies​”.

Gordon Sherriff, chief operating officer of Angel, explained that this is the company’s “core competence​”, adding that the “contract firmly places Angel in the vanguard of this important and exciting development in medicinal therapy​”.

Under the terms of the deal Angel will manufacture clinical-grade lots of ReNeuron’s second-generation CTX stem cell line for use in preclinical and clinical applications. The second-generation cell line can be frozen for shipping to multi-centre clinical trials.

ReNeuron will use the CTX cell line for proof-of-concept clinical trials with its ReN001 stem cell therapy for disabled stroke patients. Furthermore, ReNeuron is moving ReN009, a treatment for peripheral artery disease, through late preclinical and into human trials.

Manufacturing stem cells

Angel has equipped its Edinburgh facility, and received the appropriate license, to manufacture cellular therapies and this is key to the companies aim to be at the “vanguard​” of the sector.

Housed in the facility are three independent manufacturing suites allowing simultaneous multi-use. These are equipped to handle category II class organisms and use a single HVAC system to provide HEPA filtered air to each room.

Equipment in the rooms includes a 30L fermenter and a 30L cell culture bioreactor system. These are used after processes have been developed in non-current good manufacturing (GMP) cell culture suites using Wave bioreactors or up to 10L fermenters.

Related news

Show more

Related products

show more

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

The Complete Guide to eRegulatory and eSource

The Complete Guide to eRegulatory and eSource

Content provided by Florence Healthcare | 01-Apr-2023 | Insight Guide

Shifting to eRegulatory and eSource workflows is a requirement for clinical trial sites to continue to scale and grow their studies. This guide is designed...

Follow us